Kimberly Nearing’s Post

🌐 Navigating the Biopharma Landscape: Insights on VC Trends and Future Prospects 🌐 🚀 Insights on VC and Biopharma 🚀 The biopharma sector is at a critical juncture, reflecting broader economic shifts and specific industry challenges. According to recent data from Pitchbook and STAT, life science venture capital (VC) firms are on track for a record-low year of fundraising in 2024. Here’s a deep dive into the numbers and what it means for our industry: 📉 Fundraising Decline: In the first half of 2024, life science VCs raised just 15 pools of capital, a significant drop from the 53 funds last year and 85 funds in 2022. This downturn will stifle the financial support available for startups in the coming years. 🔮 Post-Covid Impact: Many VC firms are grappling with past overvaluations and investment overindulgence. The stock market (Biopharma Stocks specifically) remains far from the heights seen in previous years. 📊 STAT's Biotech VC Rankings: STAT’s fifth annual report provides a comprehensive view of how these investors are performing. This year, Flagship Pioneering leads, having raised a notable $2.6 billion for a flagship fund and $1 billion in additional capital. ⚖️ Investment Shifts: Due to a need to rebalance after heavy investments during 2020 and 2021, pension funds and sovereign wealth funds are allocating less to new VC funds. 🎲 M&A Activity: Despite these challenges, there are positive signs. Biotech mergers and acquisitions have picked up, with firms like venBio successfully raising $528 million in July 2024, partially due to successful M&A outcomes involving portfolio companies like RayzeBio, Vividion Therapeutics, Inc., and Checkmate Pharmaceuticals. 📈 Milestone Payments: High milestone payments are a critical part of M&A deals. In 2023, the median upfront payment was $305 million, with an additional $500 million contingent on R&D milestones, highlighting the importance of strategic achievements. 🤖 AI and Data Science Integration: Flagship Pioneering’s success also underscores the growing importance of #AI in biotech. Investors are keen on VC firms that integrate AI and data sciences into their operations, as this new paradigm reshapes market strategies. 🧑⚖️ Regulatory Considerations: Navigating FDA approvals and other regulatory hurdles remains critical. These milestones directly impact the payout structures in M&A deals and the overall health of the investment landscape. The biopharma sector is indeed in flux, but challenges often bring opportunities. As professionals, keeping an eye on VC trends, regulatory shifts, and technological advancements is paramount. We can use this understanding to boost professional growth and make smart investments. What are your thoughts on the current state of life science venture capital? How is your organization adapting to these shifts? Let’s discuss! #Biopharma #VentureCapital #LifeSciences #BioTech #AIinBiotech #InvestmentTrends #BiotechMergers #Innovation

When starting a biotech company, there are many challenges on the way to creating a successful business. Securing the necessary resources – be it funding, networking opportunities, or mentorship – is one of the most crucial and demanding tasks a biotech company faces in business. To efficiently identify the right incubators and investors relevant to your business, Biotechgate offers a comprehensive solution to help you navigate the search and save time and money. https://lnkd.in/gggtdjMs #investors #incubators #innovation 3 I's! Biotechgate Venture Valuation AG

No doesn’t mean never. The number of venture capital-backed series A rounds dropped 17% from 2022 to 2023, but successful fundraises netted more cash, creating a case of “haves and have nots," David Wild of Citeline’s In Vivo reported from Bio-Europe Spring in Barcelona. That trend set the stage for a panel that included Matthieu Coutet, Partner at Sofinnova Partners. The panel, which seated pharmaceutical company representatives as well as VCs, had advice for founders that boiled down to: “Don’t despair, engage early and often, even when faced with a “no.”” Despite the broader trend of fewer new company investments, Coutet said Sofinnova Partners had not slowed down investments in new companies, but just remained very selective. "When we pursue a company in the seed stage, we ensure they will be able to be financed in a series A," he said, adding that this was dependent on the company progressing toward its goals and on Sofinnova garnering interest from investors. Coutet said companies that cannot prove significant process should still come to talk, because developing "an early-stage relationship is the key for future investments." By engaging early, start-ups let investors get to know their technology, perform due diligence, and give feedback on strategy that may help the company generate convincing proof-of-concept data,” Coutet said. "We have a lot of examples in our portfolio when we have said no at some points, but we keep discussing with the researchers, with the CEO, and at some later point we see that the team was able to deliver and reach a milestone, and then we invest at a later stage," he noted. "Maybe it's a 'no' at one point, but it won't necessarily be a 'no' forever." Coutet’s last but crucial piece of advice to founders — and fellow VCs — was to find out more about what pharma companies are looking for before you talk to them. Broadly speaking, Sofinnova's interests include companies that address high unmet needs, such as neurodegenerative diseases, as well as oncology and inflammation. "We try to follow what pharma is telling us, because in the end, we work with them at a later stage for financial collaborations or acquisitions," Coutet said. Learn more about the tips shared during the opening panel discussion: https://hubs.ly/Q02qNYxz0 #BioEuropeSpring2024 #VC #investments #startups

🎊successfuly completed Expert session on Angel investment and venture capital funding ! 🎊 "Unlocking Opportunities: Navigating Angel investment and Venture capital funding for startups" conducted by Ideal Lab. #GeetaUniversity with esteemed Guest Speaker Mr.Devang raja ( Founder,"Venture Wolf"&"Angel Investor and Venture Capitalist") held on 25th July,2024. This Certificate Recognise the dedication and active involvement in learning the critical aspects of prototype development contributing to the participants professional growth and commitment to innovation. Understanding Angel Investment: Angel investors are high-net-worth individuals who provide early-stage funding to startups. They often invest their personal funds in exchange for equity or convertible debt. Angel investors bring not only capital but also mentorship, industry connections, and expertise. Venture Capital (VC) Funding Process:- VC firms invest institutional money in startups. The process involves multiple rounds (seed, Series A, B, etc.) based on the startup's growth. VCs assess the team, market potential, and scalability before investing. Pitching to Investors :- Craft a compelling pitch deck that highlights your unique value proposition. Focus on the problem you're solving, market size, competitive advantage, and financial projections. Due Diligence :- Investors conduct due diligence to assess risks and verify claims. Be prepared to share financials, legal documents, and growth plans. Remember, securing funding is just the beginning! Building a sustainable business requires dedication, adaptability, and continuous learning. #Geetauniversity #Geeta #geeta #Linkedin #University #Insitution's Innovation council #Participation

🌱 Early-Stage Science Investment: A Unique Opportunity in Biotech VC 🌱 With major VCs focused on large, later-stage funds, smaller VCs are seizing an exciting niche—investing in early-stage science. These focused funds offer more than capital; they bring hands-on support and guidance to high-risk, high-reward innovations that big funds often overlook. For biotech founders, this trend means access to engaged investors committed to their journey from lab to market. For investors, it’s a chance to back transformative ideas early and capture value from the start. 🔍 Could this shift redefine biotech funding and drive more breakthroughs?

Interesting tips for Spin-offs/Start-ups!

【#CVCF2024】 Why Start-ups Should Attend CVCF 2024: Explore new horizons in innovation and investment!   Are you a start-up looking to stand out in today's competitive venture capital market and secure funding opportunities? The Cyberport Venture Capital Forum (CVCF) is an event you won't want to miss!   Seek for Funding Opportunities: Engage directly with VCs eager to who are actively looking for promising start-ups to fund.   Direct Access to Corporate Investors: Connect face-to-face with corporations looking to work with innovative start-ups   Join Expert Mentorship: Join the Start-up Clinic for personalized 1-on-1 meetings that diagnose specific pain points and offer tailored guidance to address critical operational issues for start-ups.   Gain Visibility through Innovations Showcase: Enhance your exposure at the tech innovation marketplace to attract your next investors   Discover Investment Trends: Gain insights into the latest tech and venture trends to effectively navigate the funding landscape   Learn from Success Stories: draw inspirations with firsthand experiences shared during investor-investee dialogues and insights from elite innovators on their success formulas and effective strategies.   Explore Collaborative Partnerships: Explore potential collaborations with established companies poised to accelerate your growth and expand your market reach   Participate in Tailored Workshops: Participate in workshops specifically designed to enhance business plans and funding strategies   Enjoy Extensive Networking: Build relationships with over a thousand industry leaders and influential figures that may lead to future opportunities and partnerships. Don’t miss out on the opportunity to accelerate your start-up’s growth and make impactful connections! Secure your spot at CVCF 2024 today: https://lnkd.in/dCgEvsrV #Cyberport #CVCF2024 #venturecapital #techventuring #innovationeconomy

Sobering update on Biotech VC activity from PitchBook: "The venture capital landscape within the biopharma sector in 2023 saw a pivotal recalibration, with $29.9 billion allocated across approximately 920 transactions. Deal activity declined modestly in the latter part of the year, transitioning from $7.8 billion across 212 deals in the preceding quarter to $6.3 billion over 204 deals. Despite this, the exit activity—encompassing IPOs and M&As—totaled $18.3 billion across 94 exits, illustrating a strategic patience and selective investment ethos that pervaded the year. Q4 saw a dip to $1.8 billion from 24 deals, largely attributable to companies postponing their announcements to coincide with the J.P. Morgan Healthcare Conference in January. The year’s end marked a significant correction from the explosive growth experienced amid the height of the COVID-19 pandemic, with the exit distribution echoing a semblance of stability compared with 2022, featuring 55 IPOs and 39 acquisitions. Venture capital funding trends indicated a cautious yet discerning investment approach, with an increased median interval between funding rounds, underscoring a preference for companies showcasing mature clinical data."

Check out our latest investor chat with Krish W. Ramadurai, Partner at Harmonix ! Harmonix is a venture capital firm focused on investing in breakthrough technologies at the intersection of life sciences, healthcare, and deep technology. With a strong commitment to ethics, social impact, and scientific advancements, Harmonix aims to support and empower entrepreneurs to develop and scale their groundbreaking ideas, creating a comprehensive ecosystem for innovation and growth. For more information about Harmonix, its investment approach, and portfolio companies, please visit https://harmonixfund.com/. Some key highlights from our conversation include: 💡 Harmonix has invested in over 40 companies with $7B in enterprise value across them 💡 They invest across the spectrum of early stage companies from seed to series B 💡 When seeking VC funding, always start off with a "get to know" instead of "an ask" 💡 Founders need to develop a "must have" not a "nice to have". When pitching VCs, you need to connect the dots to show that customers want your product tomorrow and why it's imperative you have capital today Thank you Krish for taking the time to speak with us! #venturecapital #lifescience #vc #healthcare #invest #startups

"Scientists and entrepreneurs working on the world’s most urgent problems can’t solve them without funders who understand deep-tech opportunities and take long-term views. While government has a role to play, so does venture capital. It’s high time for the high rollers in VC to shift from financing the easy digital-asset classes to funding more fundamental scientific and technical advancements." https://lnkd.in/giX9yK3i #innovation #venturecapital